{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Duchenne",
    "query": {
      "condition": "Duchenne"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 237,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Duchenne&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T17:30:48.268Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03769116",
      "title": "A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne"
      ],
      "interventions": [
        {
          "name": "delandistrogene moxeparvovec",
          "type": "GENETIC"
        },
        {
          "name": "placebo",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "7 Years",
        "sex": "MALE",
        "summary": "4 Years to 7 Years · Male only"
      },
      "enrollment_count": 41,
      "start_date": "2018-12-05",
      "completion_date": "2023-08-16",
      "has_results": true,
      "last_update_posted_date": "2024-11-14",
      "last_synced_at": "2026-07-23T17:30:48.268Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Columbus, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03769116"
    },
    {
      "nct_id": "NCT03558958",
      "title": "Safety and Efficacy of P-188 NF in DMD Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "P-188 NF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phrixus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "25 Years",
        "sex": "MALE",
        "summary": "12 Years to 25 Years · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2018-08-08",
      "completion_date": "2021-09-01",
      "has_results": false,
      "last_update_posted_date": "2023-01-11",
      "last_synced_at": "2026-07-23T17:30:48.268Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03558958"
    },
    {
      "nct_id": "NCT03236662",
      "title": "(-)- Epicatechin Becker Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Becker Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "(-)-Epicatechin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Craig McDonald, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "18 Years to 70 Years · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2016-11",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2021-11-24",
      "last_synced_at": "2026-07-23T17:30:48.268Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03236662"
    },
    {
      "nct_id": "NCT02168114",
      "title": "Magnetic Resonance and Optical Imaging of Dystrophic and Damaged Muscle",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Exercising",
          "type": "OTHER"
        },
        {
          "name": "Optical and Magnetic Resonance Imaging and Spectroscopy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "10 Years to 55 Years · Male only"
      },
      "enrollment_count": 17,
      "start_date": "2014-07",
      "completion_date": "2018-01-08",
      "has_results": false,
      "last_update_posted_date": "2018-01-12",
      "last_synced_at": "2026-07-23T17:30:48.268Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02168114"
    },
    {
      "nct_id": "NCT03508947",
      "title": "Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "WVE-210201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wave Life Sciences USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "5 Years to 18 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2018-01-24",
      "completion_date": "2019-03-06",
      "has_results": false,
      "last_update_posted_date": "2019-04-08",
      "last_synced_at": "2026-07-23T17:30:48.268Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03508947"
    },
    {
      "nct_id": "NCT03333590",
      "title": "Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "rAAVrh74.MCK.GALGT2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kevin Flanigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "4 Years and older · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2017-11-06",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-07-23T17:30:48.268Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03333590"
    },
    {
      "nct_id": "NCT03863119",
      "title": "Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Vamorolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santhera Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-07-23T17:30:48.268Z",
      "location_count": 6,
      "location_summary": "Davis, California • Orlando, Florida • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03863119"
    },
    {
      "nct_id": "NCT05967351",
      "title": "A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "delandistrogene moxeparvovec",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 400,
      "start_date": "2023-09-27",
      "completion_date": "2033-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-07-23T17:30:48.268Z",
      "location_count": 22,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 19 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05967351"
    },
    {
      "nct_id": "NCT02413450",
      "title": "Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inherited Cardiac Arrythmias",
        "Long QT Syndrome (LQTS)",
        "Brugada Syndrome (BrS)",
        "Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)",
        "Early Repolarization Syndrome (ERS)",
        "Arrhythmogenic Cardiomyopathy (AC, ARVD/C)",
        "Hypertrophic Cardiomyopathy (HCM)",
        "Dilated Cardiomyopathy (DCM)",
        "Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)",
        "Normal Control Subjects"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 100,
      "start_date": "2013-08",
      "completion_date": "2031-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-07-23T17:30:48.268Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02413450"
    },
    {
      "nct_id": "NCT00018109",
      "title": "A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne"
      ],
      "interventions": [
        {
          "name": "glutamine",
          "type": "DRUG"
        },
        {
          "name": "creatine monohydrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Center for Research Resources (NCRR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "10 Years",
        "sex": "MALE",
        "summary": "5 Years to 10 Years · Male only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-07-23T17:30:48.268Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00018109"
    }
  ]
}